These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25552697)

  • 1. Role of mineralocorticoid receptor antagonists in cardiovascular disease.
    Ferrario CM; Schiffrin EL
    Circ Res; 2015 Jan; 116(1):206-13. PubMed ID: 25552697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
    Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
    Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
    Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
    Chrissobolis S
    Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
    Lother A; Moser M; Bode C; Feldman RD; Hein L
    Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The aldosterone receptor--new insights?
    Fuller P
    Expert Opin Investig Drugs; 2006 Mar; 15(3):201-3. PubMed ID: 16503757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases.
    Barrera-Chimal J; Bonnard B; Jaisser F
    Annu Rev Physiol; 2022 Feb; 84():585-610. PubMed ID: 35143332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone and end-organ damage.
    Brown NJ
    Curr Opin Nephrol Hypertens; 2005 May; 14(3):235-41. PubMed ID: 15821416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists in the treatment of hypertension and target organ damage.
    Rajagopalan S; Pitt B
    Curr Hypertens Rep; 2001 Jun; 3(3):240-8. PubMed ID: 11353575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone and its blockade: a cardiovascular and renal perspective.
    Lahera V; Cachofeiro V; Balfagon G; Rodicio JL
    ScientificWorldJournal; 2006 Apr; 6():413-24. PubMed ID: 16604252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?
    Lyngsø KS; Assersen K; Dalgaard EG; Skott O; Jensen BL; Hansen PB
    J Cardiovasc Pharmacol; 2016 Jul; 68(1):1-10. PubMed ID: 26657712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone receptor antagonists.
    Azizi M
    Ann Endocrinol (Paris); 2021 Jun; 82(3-4):179-181. PubMed ID: 32473789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid Receptor and Cardiovascular Disease.
    Buonafine M; Bonnard B; Jaisser F
    Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.
    Waanders F; de Vries LV; van Goor H; Hillebrands JL; Laverman GD; Bakker SJ; Navis G
    Curr Vasc Pharmacol; 2011 Sep; 9(5):594-605. PubMed ID: 21529330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M; Schiffrin EL
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone, organ damage and dietary salt.
    Catena C; Colussi G; Sechi LA
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):922-8. PubMed ID: 23803228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.